• ANGPTL3 sgRNAs: What the Product Record Supports

  2026-10-17

  The APExBIO listing identifies SKU R2999 as a set of three sgRNAs described as targeting the human ANGPTL3 gene, with a nominal amount of 3 μmol per sgRNA. That information supports a limited identity and mechanism overview, but provides no sequence, nuclease context, validation data, study model, readout, comparator, or evidence of editing performance.

• PDTC, NF-κB, and Nocardia Pathogenesis

  2026-10-16

  Yao et al. reported that inducible nitric oxide contributed to disease severity in experimental Nocardia farcinica infection and linked NO production in alveolar macrophages to JNK and NF-κB signaling. PDTC provided pharmacological evidence for NF-κB involvement, but the study’s strongest in vivo intervention concerned iNOS inhibition with aminoguanidine, not PDTC. The findings therefore support a mechanistic model rather than establishing that commercial Pyrrolidinedithiocarbamate ammonium is an antimicrobial or therapeutic agent.

• What PDTC Reveals in Nocardia Infection

  2026-10-16

  A literature-focused analysis of Yao et al. (2025), examining how Pyrrolidinedithiocarbamate ammonium was used as a pharmacological probe of NF-κB signaling in Nocardia farcinica infection, what the study establishes about nitric oxide, and where its mechanistic and translational limits remain.

• What the K2035 SOD Assay Measures

  2026-10-15

  APExBIO’s K2035 Superoxide Dismutase Activity Assay Kit is described as a colorimetric, coupled assay for estimating SOD activity through inhibition of WST-1 reduction by superoxide. Its documented readout represents activity in the assay system, not total reactive oxygen species, hydrogen peroxide concentration, SOD abundance, or clinical status. No identity-matched research publication or independent validation dataset is available for this product in the cited materials.

• Miransertib: Evidence and Scope of the Listing

  2026-10-15

  APExBIO’s listing identifies Miransertib as product C8430, but the available product information contains no description or identity-matched research study. This editorial therefore distinguishes catalog identity from mechanism, measurement, efficacy, and other claims that the record does not support.

• Estradiol Benzoate: What the Product Record Shows

  2026-10-14

  The APExBIO product record describes Estradiol Benzoate as a synthetic estradiol analog and estrogen receptor alpha agonist, with reported ERα binding activity in human, murine, and chicken models. Because no identity-matched paper is available, these claims should be treated as supplier-documented properties rather than independently verified study findings.

• Silybin A and the Limits of PA Evidence

  2026-10-14

  The supplied study examines praeruptorin A, not Silybin A or Silymarin. Its cell-based findings connect ERK signaling and MMP1 expression with hepatocellular carcinoma cell migration and invasion, but they do not establish that Silybin A is antimetastatic, hepatoprotective in patients, or effective in liver disease.

• Cy5 Maleimide: Documented Identity and Scope

  2026-10-13

  Cy5 maleimide (non-sulfonated), listed by APExBIO as SKU A8139, is described as a mono-reactive cyanine fluorescent dye intended for thiol-associated labeling of peptides and proteins, particularly at cysteine residues. Available evidence is limited to supplier documentation; no matched research paper was provided, so performance, comparative advantages, and application-specific outcomes cannot be independently assessed.

• GPR107, Calcium Signaling and Diabetic Nephropathy

  2026-10-13

  Xu et al. report that GPR107 deficiency aggravates diabetic nephropathy in mouse and podocyte models by altering AT1R internalization, calcium signaling, collagen IV production and matrix degradation. The findings support a mechanistic association, but they do not establish clinical efficacy or show that Fluo-4 AM was used in the study.

• MEX3A–DHRS3 in HCC: Evidence and Limits

  2026-10-12

  A 2026 pre-proof study links MEX3A to hepatocellular carcinoma progression through effects on DHRS3 mRNA stability and cell-cycle control. Its genetic, tissue, and animal-model findings are mechanistically suggestive, but the evidence remains preclinical and should not be read as clinical validation of sincalide or any proliferation assay.

• Cy5 Maleimide: Identity and Evidence Boundaries

  2026-10-12

  Cy5 maleimide (non-sulfonated), SKU A8139, is documented by APExBIO as a thiol-reactive cyanine fluorescent labeling reagent for conceptual use in protein and peptide conjugation. The available evidence is limited to supplier-provided product information; no matched research paper was identified, so biological performance, comparative advantages, and application-specific outcomes remain unverified.

• DAMGO and Central Opioid Pain Mechanisms

  2026-10-11

  A source-grounded overview of how a 2024 mouse study positioned DAMGO and morphine within a brain-to-spinal circuit associated with mechanical opioid-induced hypersensitivity and analgesic tolerance, while distinguishing reported findings from interpretation and highlighting limits on translation.

• Atorvastatin: Mechanism and Research Evidence

  2026-10-10

  Atorvastatin is an HMG-CoA reductase inhibitor used to study cholesterol metabolism, vascular biology, and cardiovascular mechanisms. Recent preclinical HCC research identified atorvastatin through Connectivity Map screening and reported ferroptosis-associated effects, but the evidence does not establish clinical anticancer efficacy.

• Pregnenolone Carbonitrile: PXR and CYP3A Evidence

  2026-10-09

  Pregnenolone Carbonitrile, also called Pregnenolone-16α-carbonitrile, is a rodent PXR agonist used to examine xenobiotic-response pathways. Evidence from a 2025 mouse study shows tissue-specific effects: hepatic CYP induction contrasted with hippocampal CYP suppression linked to glucocorticoid receptor signaling.

• METTL14–SMN Signaling and m6A: Five Questions

  2026-10-08

  A source-grounded overview of how arginine methylation may connect SMN, METTL14 and m6A regulation, with emphasis on evidence quality, interpretation, biological scope and limitations.

7841 records 1/523 page Next 12345 下5页 Last page